Alpha Synuclein Rt Quic Assay is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Real-Time Quaking-Induced Conversion (RT-QuIC) is an ultrasensitive biochemical assay that detects misfolded protein aggregates in cerebrospinal fluid (CSF) and other biological tissues. Originally developed for prion diseases, RT-QuIC has been adapted to detect α-synuclein aggregates in [Parkinson's disease](/diseases/parkinsons-disease), Dementia with Lewy Bodies, and Multiple System Atrophy, providing a powerful diagnostic tool for synucleinopathies[@fairfoul2016].
Alpha Synuclein Rt Quic Assay is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Real-Time Quaking-Induced Conversion (RT-QuIC) is an ultrasensitive biochemical assay that detects misfolded protein aggregates in cerebrospinal fluid (CSF) and other biological tissues. Originally developed for prion diseases, RT-QuIC has been adapted to detect α-synuclein aggregates in [Parkinson's disease](/diseases/parkinsons-disease), Dementia with Lewy Bodies, and Multiple System Atrophy, providing a powerful diagnostic tool for synucleinopathies[@fairfoul2016].
[Alpha-Synuclein](/proteins/alpha-synuclein) RT-QuIC (Real-Time Quaking-Induced Conversion) is an ultrasensitive diagnostic assay that detects misfolded [alpha-synuclein](/proteins/alpha-synuclein) aggregates in cerebrospinal fluid (CSF) and other biological samples. It exploits the ability of pathological alpha-synuclein to template the conversion of recombinant alpha-synuclein into amyloid fibrils.
This assay enables early and accurate diagnosis of Parkinson's Disease, Dementia with Lewy Bodies, and Multiple System Atrophy by detecting prion-like alpha-synuclein seeds up to a decade before clinical symptoms appear.
RT-QuIC exploits the seed-dependent aggregation properties of misfolded proteins. The assay works as follows:
RT-QuIC detects α-synuclein seeds in CSF with high sensitivity (85-95%) and specificity (95-100%) for Parkinson's disease[@rossi2020]. This represents a major advance because:
RT-QuIC shows high sensitivity (95-100%) for DLB, making it useful for differentiating from other dementias[@bongianni2017]:
| Condition | Sensitivity | Specificity |
|-----------|-------------|-------------|
| Parkinson's Disease | 85-95% | 95-100% |
| Dementia with Lewy Bodies | 95-100% | 90-98% |
| Multiple System Atrophy | 80-90% | 95-100% |
| Progressive Supranuclear Palsy | 10-20% | 95-100% |
| [Alzheimer's Disease](/diseases/alzheimers-disease) | 0-5% | 99-100% |
RT-QuIC can detect α-synuclein aggregates characteristic of MSA (predominantly neuronal, not glial)[@singer2020]. The assay shows:
| Factor | Effect | Recommendation |
|--------|--------|----------------|
| Blood contamination | False positives | Avoid RBC contamination |
| Storage time | Decreased sensitivity | Test within 6 months |
| Repeated freeze-thaw | Reduced signal | Limit to 3 cycles |
| Sample age | Variable | Fresh testing preferred |
RT-QuIC demonstrates excellent diagnostic performance in large validation studies:
Parkinson's Disease:
| Feature | RT-QuIC | ELISA |
|---------|---------|-------|
| Detects | Seed-competent aggregates | Total α-synuclein |
| Sensitivity | Much higher | Moderate |
| Specificity | Higher | Lower |
| Turnaround | 2-5 days | 1-2 days |
| Feature | RT-QuIC | Skin Biopsy |
|---------|---------|-------------|
| Invasiveness | Minimal (LP) | Moderate (biopsy) |
| Sensitivity | 85-100% | 75-90% |
| Standardization | Good | Variable |
| Cost | Lower | Higher |
RT-QuIC enables:
RT-QuIC is being incorporated into clinical trials as:
Emerging methods aim to detect α-synuclein seeds in blood samples, which would enable:
Combining α-synuclein RT-QuIC with other biomarkers:
The study of Alpha Synuclein Rt Quic Assay has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.